Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
YMAB
Upturn stock ratingUpturn stock rating

Y mAbs Therapeutics (YMAB)

Upturn stock ratingUpturn stock rating
$8.51
Last Close (24-hour delay)
Profit since last BUY-0.12%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: YMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.6

1 Year Target Price $8.6

Analysts Price Target For last 52 week
$8.6 Target price
52w Low $3.55
Current$8.51
52w High $16.11

Analysis of Past Performance

Type Stock
Historic Profit 41.91%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 387.14M USD
Price to earnings Ratio -
1Y Target Price 8.6
Price to earnings Ratio -
1Y Target Price 8.6
Volume (30-day avg) 10
Beta 0.56
52 Weeks Range 3.55 - 16.11
Updated Date 08/16/2025
52 Weeks Range 3.55 - 16.11
Updated Date 08/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.5

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-08
When -
Estimate -0.26
Actual -0.07

Profitability

Profit Margin -26.03%
Operating Margin (TTM) -28.7%

Management Effectiveness

Return on Assets (TTM) -8.67%
Return on Equity (TTM) -24.31%

Valuation

Trailing PE -
Forward PE 119.05
Enterprise Value 327966338
Price to Sales(TTM) 4.53
Enterprise Value 327966338
Price to Sales(TTM) 4.53
Enterprise Value to Revenue 3.84
Enterprise Value to EBITDA -0.43
Shares Outstanding 45438400
Shares Floating 25152892
Shares Outstanding 45438400
Shares Floating 25152892
Percent Insiders 11.97
Percent Institutions 69.64

ai summary icon Upturn AI SWOT

Y mAbs Therapeutics

stock logo

Company Overview

overview logo History and Background

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company founded in 2015. It focuses on developing and commercializing novel antibody-based therapeutic products for the treatment of cancer, particularly in pediatric populations. Initially focused on neuroblastoma, Y-mAbs has expanded to other cancer types. The company is built upon technology licensed from Memorial Sloan Kettering Cancer Center.

business area logo Core Business Areas

  • Oncology Therapeutics Development: Focuses on the research, development, and commercialization of antibody-based therapies for various cancers.
  • Pediatric Cancer Focus: Specializes in developing treatments for pediatric cancers with high unmet medical needs.

leadership logo Leadership and Structure

Y-mAbs is led by a management team with experience in oncology and biopharmaceutical development. The organizational structure includes departments for research and development, clinical operations, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • DANYELZA (naxitamab-gqgk): A GD2-binding monoclonal antibody approved for the treatment of high-risk neuroblastoma in pediatric and adult patients who have demonstrated a partial response, minor response, or stable disease to prior first-line therapy. Market share data is difficult to ascertain precisely but Danyelza is a key player in the neuroblastoma treatment landscape. Competitors include standard chemotherapy regimens and other investigational therapies targeting neuroblastoma.
  • OMBLASTYS (omezatamab): An investigational drug product for the treatment of DIPG that is in phase III clinical trials. As an investigational therapy it has no market share as of October 26, 2024. Competitors would include radiation therapy and other experimental DIPG therapies.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The oncology market is a significant segment, driven by increasing cancer incidence and advances in targeted therapies and immunotherapies.

Positioning

Y-mAbs is positioned as a specialized oncology company focused on pediatric cancers. Its competitive advantage lies in its proprietary antibody technologies and its focus on addressing unmet needs in rare pediatric cancers.

Total Addressable Market (TAM)

The total addressable market (TAM) for neuroblastoma and other pediatric cancers is substantial, with significant unmet needs. The global neuroblastoma market is estimated to be in the hundreds of millions of dollars and growing. Y-mAbs is positioned to capture a significant share of this market with its approved and investigational therapies.

Upturn SWOT Analysis

Strengths

  • FDA-approved product (DANYELZA)
  • Proprietary antibody technologies
  • Focus on underserved pediatric cancer market
  • Experienced management team
  • Strong relationships with leading cancer centers

Weaknesses

  • Dependence on a limited number of products
  • Commercialization challenges for rare diseases
  • High cash burn rate
  • Regulatory hurdles for new drug approvals
  • Reliance on external manufacturing partners

Opportunities

  • Expansion into new cancer indications
  • Partnerships and collaborations with other pharmaceutical companies
  • Potential for accelerated regulatory pathways for pediatric cancer therapies
  • Geographic expansion into new markets
  • Development of next-generation antibody therapies

Threats

  • Competition from established pharmaceutical companies
  • Patent expirations and generic entry
  • Clinical trial failures
  • Regulatory setbacks
  • Economic downturns and healthcare spending constraints

Competitors and Market Share

competitor logo Key Competitors

  • BMRN
  • NKTR
  • MRTX

Competitive Landscape

Y-mAbs faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for cancer. Its advantages include its focus on pediatric cancers and its proprietary antibody technologies. Disadvantages include its limited product portfolio and commercialization challenges.

Growth Trajectory and Initiatives

Historical Growth: Y-mAbs' historical growth has been driven by the approval and commercialization of DANYELZA. Revenue growth has been variable and impacted by factors such as market access and reimbursement.

Future Projections: Future growth projections depend on the success of its pipeline candidates and the expansion of DANYELZA's market reach. Analyst estimates vary widely and are subject to change. Refer to analyst reports for specific projections.

Recent Initiatives: Recent strategic initiatives include advancing the clinical development of its pipeline candidates, expanding its commercial infrastructure, and exploring partnerships and collaborations.

Summary

Y-mAbs is a biopharmaceutical company focused on pediatric oncology, primarily neuroblastoma, where it has an approved product. While it has a focused pipeline and some successes, it operates at a loss and needs additional therapy successes. Cash burn is a constant concern, so investors should carefully monitor progress and financial results. Success of Omblastys could alter the outlook considerably.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Y-mAbs Therapeutics Investor Relations
  • SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximate and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Y mAbs Therapeutics

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2018-09-21
CEO, President & Director Mr. Michael Rossi
Sector Healthcare
Industry Biotechnology
Full time employees 104
Full time employees 104

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.